Market reports, regulatory updates, and strategic perspectives from our team on the ground.
The GCC pharmaceutical market is projected to exceed $25 billion by 2028. But the real story is structural: national health strategies, mandatory localization requirements, and accelerating regulatory harmonization are reshaping how global companies must approach the region.
The Saudi Food and Drug Authority's new accelerated review pathway for innovative medicines represents a significant shift. We break down eligibility criteria, timelines, and strategic implications.
The decisions made in the first three months of a UAE market entry — on pricing, distribution, and stakeholder engagement — have an outsized impact on long-term commercial performance.
Egypt's pharmaceutical market is the largest in Africa and a critical gateway to the broader North Africa region. Understanding its regulatory dynamics, pricing controls, and distribution landscape is essential for any MENA strategy.
The Gulf Cooperation Council's push toward regulatory harmonization has made significant progress — but important gaps remain. We assess the current state and implications for market access strategy.
Government payers dominate pharmaceutical procurement across the GCC. Understanding their decision-making frameworks, formulary processes, and value evidence requirements is non-negotiable for market access success.
Subscribe to receive our latest market reports and regulatory updates directly.